Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01504893
Other study ID # ALI01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2013
Est. completion date September 2017

Study information

Verified date November 2022
Source Azienda Ospedaliera S. Maria della Misericordia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if a protective ventilatory strategy during one-lung ventilation (OLV) based on low tidal volume, PEEP and alveolar recruitment maneuver can reduce Acute Respiratory Distress Syndrome (ARDS) and Postoperative pulmonary complications (PPCs) after major pulmonary resection. Primary endpoint: Evaluation of postoperative ARDS incidence Secondary endpoint: Evaluation od PPC incidence and postoperative outcomes (other complications, unplanned Intensive Care Admission, hospital and ICU length of stay, in-hospital mortality)


Description:

Pulmonary postoperative complications (PPCs) are the most frequent adverse events after thoracic surgery. Acute respiratory distress syndrome (ARDS) is the most severe among PPCs. Injurious mechanical ventilation is a recognized risk factor associated with ARDS and PPCs after major thoracic surgery. International literature reports a wide use of tidal volume around 5-6 ml/kg predicted body weight (PBW) during one lung ventilation (OLV) but variable use of PEEP and alveolar recruitment maneuver (ARM). The aim of this multicenter, randomized, single blind study is to determine if a protective ventilatory strategy during OLV based on low tidal volume, PEEP and alveolar recruitment maneuver compared to conventional strategy can reduce ARDS and PPCs after major pulmonary resection. Primary outcome is the incidence of in-hospital ARDS. Secondary outcomes are in-hospital incidence of postoperative pulmonary complications (PPCs), major cardiovascular events, unplanned Intensive Care Unit admission, in-hospital length of stay and mortality RANDOMIZATION Patients are randomly assigned to receive protective or conventional OLV according to a computer-generated randomization list (1:1 ratio) before anesthesia induction. Patients are blinded to the treatment. Anesthesiologists and surgeons are unblinded to the treatment during the surgical procedure and the postoperative outcome assessment. MEASUREMENTS Intraoperative collection of ventilatory settings, airway pressures, arterial blood gases analysis at the following time points: T1: two lung ventilation in supine position before placing the patient in lateral decubitus; T2: 30 minutes after OLV start; T3: 60 minutes after OLV start; T4: 20 minutes after lobectomy/pneumonectomy (during OLV); T5: 15 minutes after ARM in supine position and during two lung ventilation. Postoperative data collection 1, 12, 24, 36, 48 hours after surgery and at discharge. Arterial blood gas analysis will be performed 1 hour after extubation and 24 and 72 hours after surgery (or in case of respiratory insufficiency).


Recruitment information / eligibility

Status Completed
Enrollment 984
Est. completion date September 2017
Est. primary completion date August 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients = 18 years - ASA IV - Elective thoracotomies or thoracoscopic major lung resection surgery (lobectomy, bilobectomy, pneumonectomy) Exclusion Criteria: - Emergency surgery - Wedge resection or atypical resection - Non-resective lung surgery requiring OLV - Patients < 18 years - BMI < 20 and BMI > 29 - Heart disease with ejection fraction <50% and/or severe valvulopathy - Pulmonary hypertension - Renal failure requiring dialytic treatment - Drug addiction - Mental retardation, depression and psychiatric disease - Motor or sensory deficit - Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Protective one lung ventilation
Low tidal volume, PEEP and alveolar recruitment maneuver

Locations

Country Name City State
Italy ASST Papa Giovanni XXIII Bergamo
Italy IRCCS Policlinico Sant'Orsola-Malpighi Bologna
Italy Ospedale Centrale Bolzano
Italy Azienda Ospedaliera Brotzu - Ospedale Oncologico Businco Cagliari
Italy IRCCS Ospedale Policlinico San Martino Genova
Italy Fondazione IRCCS Istituto Nazionale Tumori Milan
Italy IRCCS Ospedale San Raffaele Milan
Italy Azienda Ospedaliera-Universitaria Modena
Italy Istituto Nazionale Tumori Fondazione Pascale Napoli
Italy Azienda Ospedaliero-Universitaria Padova
Italy IRCCS Centro di Riferimento Oncologico della Basilicata Rionero In Vulture
Italy Istituto Nazionale Tumori Regina Elena Rome
Italy Azienda Ospedaliera Universitaria Senese Siena
Italy Ospedale di Cattinara Trieste
Italy Department of Anesthesia and Intensive Care Unit Udine
Italy Ospedale di Circolo e Fondazione Macchi Varese

Sponsors (1)

Lead Sponsor Collaborator
Azienda Ospedaliera S. Maria della Misericordia

Country where clinical trial is conducted

Italy, 

References & Publications (2)

Licker M, Diaper J, Villiger Y, Spiliopoulos A, Licker V, Robert J, Tschopp JM. Impact of intraoperative lung-protective interventions in patients undergoing lung cancer surgery. Crit Care. 2009;13(2):R41. doi: 10.1186/cc7762. Epub 2009 Mar 24. — View Citation

Yang M, Ahn HJ, Kim K, Kim JA, Yi CA, Kim MJ, Kim HJ. Does a protective ventilation strategy reduce the risk of pulmonary complications after lung cancer surgery?: a randomized controlled trial. Chest. 2011 Mar;139(3):530-537. doi: 10.1378/chest.09-2293. Epub 2010 Sep 9. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Acute Respiratory Distress Syndrome (ARDS) incidence incidence of ARDS (%) Hospital stay (7 days average expected)
Secondary Postoperative pulmonary complications (PPCs) Incidence of PPCs (%) Hospital stay (7 days average expected)
Secondary In-hospital mortality To determine mortality (%) Hospital stay (7 days average aspected)
Secondary Postoperative complications To determine how many patients (%) would have any postoperative complications Hospital stay (7 days average expected)
Secondary Unplanned Intensive Care Unit (ICU) admission To determine how many patients would require an ICU admission (%) Hospital stay (7 days average aspected)
Secondary Intensive Care Unit (ICU) Length of stay Length of stay in ICU (days) Hospital stay (7 days average aspected)
Secondary Length of hospital stay Duration of hospital length of stay Hospital stay (7 days average expected)
See also
  Status Clinical Trial Phase
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Recruiting NCT05535543 - Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
Completed NCT04695392 - Restore Resilience in Critically Ill Children N/A
Terminated NCT04972318 - Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia N/A
Completed NCT04534569 - Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
Completed NCT04078984 - Driving Pressure as a Predictor of Mechanical Ventilation Weaning Time on Post-ARDS Patients in Pressure Support Ventilation.
Completed NCT04451291 - Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure N/A
Not yet recruiting NCT06254313 - The Role of Cxcr4Hi neutrOPhils in InflueNza
Not yet recruiting NCT04798716 - The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19 Phase 1/Phase 2
Withdrawn NCT04909879 - Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome Phase 2
Not yet recruiting NCT02881385 - Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation N/A
Terminated NCT02867228 - Noninvasive Estimation of Work of Breathing N/A
Completed NCT02545621 - A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
Withdrawn NCT02253667 - Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients N/A
Completed NCT02232841 - Electrical Impedance Imaging of Patients on Mechanical Ventilation N/A
Completed NCT02889770 - Dead Space Monitoring With Volumetric Capnography in ARDS Patients N/A
Withdrawn NCT01927237 - Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide N/A
Completed NCT01680783 - Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure N/A
Completed NCT02814994 - Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients N/A
Completed NCT02214576 - High Flow Nasal Canula Oxygen Helps Preoxygenate ARDS Patients N/A